产品名称	Zagotenemab (anti-Tau), 微管相关蛋白 tau 抑制剂
别名	泽格特奈单抗 \| 扎戈替尼单抗（抗 Tau）
英文别名	AI413597 antibody \| AW045860 antibody \| DDPAC antibody \| FLJ31424 antibody \| FTDP 17 antibody \| G protein beta1/gamma2 subunit interacting factor 1 antibody \| MAPT antibody \| MAPTL antibody \| MGC134287 antibody \| MGC138549 antibody \| MGC156663 antibody \|
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	MAPT
种属反应性	人(Human),小鼠(Mouse)
偶联	Unconjugated
作用类型	抑制剂
作用机制	微管相关蛋白 tau 抑制剂

产品属性

克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG4SP
轻链亚型	kappa
SDS-PAGE	27.4 kDa (Light Chain) & 53.1 kDa (Heavy Chain), under reducing conditions; 186.5 kDa, under non-reducing conditions.
纯化方法	Protein A purified
纯度	>95%
物理外观	Liquid
储存缓冲液	Supplied as a 0.22 μm filtered solution in 100mM Pro-AC, 20mM Arg, pH 5.0
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息	2019133-28-7
分子类型	抗体

图片

SEC: Zagotenemab (anti-Tau) (Ab176314)

Zagotenemab (anti-Tau) (Ab176314) - SEC
The purity of Zagotenemab (anti-Tau) (Ab176314) is more than 95% verified by HPLC.

关联靶点（人）

MAPT Tclin 微管相关蛋白 tau(Microtubule-associated protein tau) (0 活性数据)

点击查看靶蛋白信息： MAPT

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

MAPT Tclin Microtubule-associated protein tau (95507 活性数据)

点击查看靶蛋白信息： MAPT

活性类型	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

MAPT Tclin KEAP1/Microtubule-associated protein tau (1 活性数据)

点击查看靶蛋白信息： MAPT

活性类型	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

MAPT Tclin KEAP1/Cullin-3/Microtubule-associated protein tau (13 活性数据)

点击查看靶蛋白信息： MAPT

活性类型	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

安全和危险性（GHS）

SDS英文版

技术规格说明书

技术规格说明书

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到3个结果

批号(Lot Number)	证书类型	日期	货号
ZJ24F1113262	分析证书	24-11-04	Ab176314
ZJ24F1113261	分析证书	24-11-04	Ab176314
ZJ24F1113260	分析证书	24-11-04	Ab176314

可替换产品

参考文献

1. Shao X, Carpenter GM, Desmond TJ, Sherman P, Quesada CA, Fawaz M, Brooks AF, Kilbourn MR, Albin RL, Frey KA et al.. (2012) Evaluation of [(11)C]N-Methyl Lansoprazole as a Radiopharmaceutical for PET Imaging of Tau Neurofibrillary Tangles.. ACS Med Chem Lett, 3 (11): (936-41). [PMID:24900410] [10.1021/op500134e]
2. Pickering-Brown S, Baker M, Yen SH, Liu WK, Hasegawa M, Cairns N, Lantos PL, Rossor M, Iwatsubo T, Davies Y et al.. (2000) Pick's disease is associated with mutations in the tau gene.. Ann Neurol, 48 (6): (859-67). [PMID:11117542] [10.1021/op500134e]
3. Rosso SM, van Herpen E, Deelen W, Kamphorst W, Severijnen LA, Willemsen R, Ravid R, Niermeijer MF, Dooijes D, Smith MJ et al.. (2002) A novel tau mutation, S320F, causes a tauopathy with inclusions similar to those in Pick's disease.. Ann Neurol, 51 (3): (373-6). [PMID:11891833] [10.1021/op500134e]
4. Neumann M, Schulz-Schaeffer W, Crowther RA, Smith MJ, Spillantini MG, Goedert M, Kretzschmar HA. (2001) Pick's disease associated with the novel Tau gene mutation K369I.. Ann Neurol, 50 (4): (503-13). [PMID:11601501] [10.1021/op500134e]
5. Rizzu P, Van Swieten JC, Joosse M, Hasegawa M, Stevens M, Tibben A, Niermeijer MF, Hillebrand M, Ravid R, Oostra BA et al.. (1999) High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands.. Am J Hum Genet, 64 (2): (414-21). [PMID:9973279] [10.1021/op500134e]
6. Yoshida H, Crowther RA, Goedert M. (2002) Functional effects of tau gene mutations deltaN296 and N296H.. J Neurochem, 80 (3): (548-51). [PMID:11906000] [10.1021/op500134e]
7. Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, Andreadis A, Wiederholt WC, Raskind M, Schellenberg GD. (1998) Tau is a candidate gene for chromosome 17 frontotemporal dementia.. Ann Neurol, 43 (6): (815-25). [PMID:9629852] [10.1021/op500134e]
8. Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA. (2017) The Essential Medicinal Chemistry of Curcumin.. J Med Chem, 60 (5): (1620-1637). [PMID:28074653] [10.1021/op500134e]
9. Matsumura K, Ono M, Kimura H, Ueda M, Nakamoto Y, Togashi K, Okamoto Y, Ihara M, Takahashi R, Saji H.. (2012) (18)F-labeled phenyldiazenyl benzothiazole for in vivo imaging of neurofibrillary tangles in Alzheimer's disease brains.. ACS Med Chem Lett, 3 (1): (58-62). [PMID:24900371] [10.1021/ml200230e]
10. Watanabe H, Ono M, Kimura H, Matsumura K, Yoshimura M, Okamoto Y, Ihara M, Takahashi R, Saji H.. (2012) Synthesis and biological evaluation of novel oxindole derivatives for imaging neurofibrillary tangles in Alzheimer's disease.. Bioorg Med Chem Lett, 22 (17): (5700-5703). [PMID:22832319] [10.1016/j.bmcl.2012.06.086]
11. Gu J, Anumala UR, Lo Monte F, Kramer T, Heyny von Haußen R, Hölzer J, Goetschy-Meyer V, Mall G, Hilger I, Czech C, Schmidt B.. (2012) 2-Styrylindolium based fluorescent probes visualize neurofibrillary tangles in Alzheimer's disease.. Bioorg Med Chem Lett, 22 (24): (7667-7671). [PMID:23127889] [10.1016/j.bmcl.2012.09.109]
12. Trippier PC, Jansen Labby K, Hawker DD, Mataka JJ, Silverman RB.. (2013) Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.. J Med Chem, 56 (8): (3121-3147). [PMID:23458846] [10.1021/jm3015926]
13. Bulic B, Pickhardt M, Mandelkow E.. (2013) Progress and developments in tau aggregation inhibitors for Alzheimer disease.. J Med Chem, 56 (11): (4135-4155). [PMID:23484434] [10.1021/jm3017317]
14. Matsumura K, Ono M, Yoshimura M, Kimura H, Watanabe H, Okamoto Y, Ihara M, Takahashi R, Saji H.. (2013) Synthesis and biological evaluation of novel styryl benzimidazole derivatives as probes for imaging of neurofibrillary tangles in Alzheimer's disease.. Bioorg Med Chem, 21 (11): (3356-3362). [PMID:23601814] [10.1016/j.bmc.2013.02.054]
15. Gan C, Zhao Z, Nan DD, Yin B, Hu J.. (2014) Homoisoflavonoids as potential imaging agents for β-amyloid plaques in Alzheimer's disease.. Eur J Med Chem, 76 (125-131). [PMID:24583352] [10.1016/j.ejmech.2014.02.020]
16. Viayna E, Sola I, Bartolini M, De Simone A, Tapia-Rojas C, Serrano FG, Sabaté R, Juárez-Jiménez J, Pérez B, Luque FJ, Andrisano V, Clos MV, Inestrosa NC, Muñoz-Torrero D.. (2014) Synthesis and multitarget biological profiling of a novel family of rhein derivatives as disease-modifying anti-Alzheimer agents.. J Med Chem, 57 (6): (2549-2567). [PMID:24568372] [10.1021/jm401824w]
17. Chu W, Zhou D, Gaba V, Liu J, Li S, Peng X, Xu J, Dhavale D, Bagchi DP, d'Avignon A, Shakerdge NB, Bacskai BJ, Tu Z, Kotzbauer PT, Mach RH.. (2015) Design, Synthesis, and Characterization of 3-(Benzylidene)indolin-2-one Derivatives as Ligands for α-Synuclein Fibrils.. J Med Chem, 58 (15): (6002-6017). [PMID:26177091] [10.1021/acs.jmedchem.5b00571]
18. Sun G, Wang J, Guo X, Lei M, Zhang Y, Wang X, Shen X, Hu L.. (2018) Design, synthesis and biological evaluation of LX2343 derivatives as neuroprotective agents for the treatment of Alzheimer's disease.. Eur J Med Chem, 145 (622-633). [PMID:29339255] [10.1016/j.ejmech.2017.12.080]
19. Lu M, Liu T, Jiao Q, Ji J, Tao M, Liu Y, You Q, Jiang Z.. (2018) Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway.. Eur J Med Chem, 146 (251-259). [PMID:29407955] [10.1016/j.ejmech.2018.01.063]
20. Gandini A, Bartolini M, Tedesco D, Martinez-Gonzalez L, Roca C, Campillo NE, Zaldivar-Diez J, Perez C, Zuccheri G, Miti A, Feoli A, Castellano S, Petralla S, Monti B, Rossi M, Moda F, Legname G, Martinez A, Bolognesi ML.. (2018) Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors.. J Med Chem, 61 (17): (7640-7656). [PMID:30078314] [10.1021/acs.jmedchem.8b00610]
21. Pérez-Areales FJ, Turcu AL, Barniol-Xicota M, Pont C, Pivetta D, Espargaró A, Bartolini M, De Simone A, Andrisano V, Pérez B, Sabate R, Sureda FX, Vázquez S, Muñoz-Torrero D.. (2019) A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.. Eur J Med Chem, 180 (613-626). [PMID:31351393] [10.1016/j.ejmech.2019.07.051]
22. Dinda B, Dinda M, Kulsi G, Chakraborty A, Dinda S.. (2019) Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.. Eur J Med Chem, 169 (185-199). [PMID:30877973] [10.1016/j.ejmech.2019.03.009]
23. Pérez-Areales FJ,Garrido M,Aso E,Bartolini M,De Simone A,Espargaró A,Ginex T,Sabate R,Pérez B,Andrisano V,Puigoriol-Illamola D,Pallàs M,Luque FJ,Loza MI,Brea J,Ferrer I,Ciruela F,Messeguer A,Muñoz-Torrero D. (2020) Centrally Active Multitarget Anti-Alzheimer Agents Derived from the Antioxidant Lead CR-6.. J Med Chem, 63 (17): (9360-9390). [PMID:32706255] [10.1021/acs.jmedchem.0c00528]
24. Andreadis, A A, Brown, W M WM and Kosik, K S KS.. (1992) Structure and novel exons of the human tau gene.. Biochemistry, (3): [PMID:1420178]
25. Hasegawa, M M and 5 more authors.. (1992) Protein sequence and mass spectrometric analyses of tau in the Alzheimer's disease brain.. The Journal of biological chemistry, (25): [PMID:1512244]
26. Goedert, M M, Crowther, R A RA and Garner, C C CC.. (1991) Molecular characterization of microtubule-associated proteins tau and MAP2.. Trends in neurosciences, [PMID:1713721]
27. Lee, V M VM, Balin, B J BJ, Otvos, L L and Trojanowski, J Q JQ.. (1991) A68: a major subunit of paired helical filaments and derivatized forms of normal Tau.. Science (New York, N.Y.), (8): [PMID:1899488]
28. Jakes, R R, Novak, M M, Davison, M M and Wischik, C M CM.. (1991) Identification of 3- and 4-repeat tau isoforms within the PHF in Alzheimer's disease.. The EMBO journal, [PMID:1915258]
29. Goedert, M M, Spillantini, M G MG, Jakes, R R, Rutherford, D D and Crowther, R A RA.. (1989) Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease.. Neuron, [PMID:2484340]
30. Mori, H H and 5 more authors.. (1989) A distinct form of tau is selectively incorporated into Alzheimer's paired helical filaments.. Biochemical and biophysical research communications, (31): [PMID:2495000]
31. Goedert, M M, Spillantini, M G MG, Potier, M C MC, Ulrich, J J and Crowther, R A RA.. (1989) Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain.. The EMBO journal, [PMID:2498079]
32. Lee, G G, Neve, R L RL and Kosik, K S KS.. (1989) The microtubule binding domain of tau protein.. Neuron, [PMID:2516729]
33. Goedert, M M, Wischik, C M CM, Crowther, R A RA, Walker, J E JE and Klug, A A.. (1988) Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:3131773]
34. Drewes, G G and 7 more authors.. (1995) Microtubule-associated protein/microtubule affinity-regulating kinase (p110mark). A novel protein kinase that regulates tau-microtubule interactions and dynamic instability by phosphorylation at the Alzheimer-specific site serine 262.. The Journal of biological chemistry, (31): [PMID:7706316]
35. and Paudel, H K HK.. (1997) The regulatory Ser262 of microtubule-associated protein tau is phosphorylated by phosphorylase kinase.. The Journal of biological chemistry, (17): [PMID:8999860]
36. Nacharaju, P P, Ko, L L and Yen, S H SH.. (1997) Characterization of in vitro glycation sites of tau.. Journal of neurochemistry, [PMID:9326300]
37. Illenberger, S S and 9 more authors.. (1998) The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer's disease.. Molecular biology of the cell, [PMID:9614189]
38. Hutton, M M and 50 more authors.. (1998) Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17.. Nature, (18): [PMID:9641683]
39. Sengupta, A A and 5 more authors.. (1998) Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules.. Archives of biochemistry and biophysics, (15): [PMID:9735171]
40. Dumanchin, C C and 12 more authors.. (1998) Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism.. Human molecular genetics, [PMID:9736786]
41. Clark, L N LN and 18 more authors.. (1998) Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17.. Proceedings of the National Academy of Sciences of the United States of America, (27): [PMID:9789048]
42. Iijima, M M and 12 more authors.. (1999) A distinct familial presenile dementia with a novel missense mutation in the tau gene.. Neuroreport, (25): [PMID:10208578]
43. Nacharaju, P P and 6 more authors.. (1999) Accelerated filament formation from tau protein with specific FTDP-17 missense mutations.. FEBS letters, (26): [PMID:10214944]
44. Bugiani, O O and 15 more authors.. (1999) Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau.. Journal of neuropathology and experimental neurology, [PMID:10374757]
45. Delisle, M B MB and 8 more authors.. (1999) A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a tauopathy with dementia and supranuclear palsy.. Acta neuropathologica, [PMID:10412802]
46. Yasuda, M M and 13 more authors.. (1999) A mutation in the microtubule-associated protein tau in pallido-nigro-luysian degeneration.. Neurology, (11): [PMID:10489057]
47. Higgins, J J JJ, Adler, R L RL and Loveless, J M JM.. (1999) Mutational analysis of the tau gene in progressive supranuclear palsy.. Neurology, (22): [PMID:10534245]
48. Sperfeld, A D AD and 10 more authors.. (1999) FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation.. Annals of neurology, [PMID:10553987]
49. Murrell, J R JR and 10 more authors.. (1999) Tau gene mutation G389R causes a tauopathy with abundant pick body-like inclusions and axonal deposits.. Journal of neuropathology and experimental neurology, [PMID:10604746]
50. Maas, T T, Eidenmüller, J J and Brandt, R R.. (2000) Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments.. The Journal of biological chemistry, (26): [PMID:10747907]
51. Arima, K K and 9 more authors.. (2000) Two brothers with frontotemporal dementia and parkinsonism with an N279K mutation of the tau gene.. Neurology, (9): [PMID:10802785]
52. Goedert, M M and Spillantini, M G MG.. (2000) Tau mutations in frontotemporal dementia FTDP-17 and their relevance for Alzheimer's disease.. Biochimica et biophysica acta, (26): [PMID:10899436]
53. Yasuda, M M and 7 more authors.. (2000) A Japanese patient with frontotemporal dementia and parkinsonism by a tau P301S mutation.. Neurology, (24): [PMID:11071507]
54. Rizzini, C C and 8 more authors.. (2000) Tau gene mutation K257T causes a tauopathy similar to Pick's disease.. Journal of neuropathology and experimental neurology, [PMID:11089577]
55. Lippa, C F CF and 10 more authors.. (2000) Frontotemporal dementia with novel tau pathology and a Glu342Val tau mutation.. Annals of neurology, [PMID:11117541]
56. Pastor, P P and 7 more authors.. (2001) Familial atypical progressive supranuclear palsy associated with homozigosity for the delN296 mutation in the tau gene.. Annals of neurology, [PMID:11220749]
57. Connell, J W JW and 7 more authors.. (2001) Effects of FTDP-17 mutations on the in vitro phosphorylation of tau by glycogen synthase kinase 3beta identified by mass spectrometry demonstrate certain mutations exert long-range conformational changes.. FEBS letters, (23): [PMID:11278002]
58. Wintjens, R R and 6 more authors.. (2001) 1H NMR study on the binding of Pin1 Trp-Trp domain with phosphothreonine peptides.. The Journal of biological chemistry, (6): [PMID:11313338]
59. Iseki, E E and 9 more authors.. (2001) Familial frontotemporal dementia and parkinsonism with a novel N296H mutation in exon 10 of the tau gene and a widespread tau accumulation in the glial cells.. Acta neuropathologica, [PMID:11585254]
60. Saito, Y Y and 7 more authors.. (2002) Early-onset, rapidly progressive familial tauopathy with R406W mutation.. Neurology, (12): [PMID:11889249]
61. Hayashi, Shintaro S and 7 more authors.. (2002) Late-onset frontotemporal dementia with a novel exon 1 (Arg5His) tau gene mutation.. Annals of neurology, [PMID:11921059]
62. Poorkaj, Parvoneh P and 10 more authors.. (2002) An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype.. Annals of neurology, [PMID:12325083]
63. Tsuboi, Y Y and 16 more authors.. (2002) Clinical and genetic studies of families with the tau N279K mutation (FTDP-17).. Neurology, (10): [PMID:12473774]
64. Kobayashi, Tomonori T and 11 more authors.. (2003) A novel L266V mutation of the tau gene causes frontotemporal dementia with a unique tau pathology.. Annals of neurology, [PMID:12509859]
65. Rademakers, R R and 6 more authors.. (2003) Tau (MAPT) mutation Arg406Trp presenting clinically with Alzheimer disease does not share a common founder in Western Europe.. Human mutation, [PMID:14517953]
66. Nicholl, David J DJ and 8 more authors.. (2003) An English kindred with a novel recessive tauopathy and respiratory failure.. Annals of neurology, [PMID:14595660]
67. Li, Guibin G, Yin, Haishan H and Kuret, Jeff J.. (2004) Casein kinase 1 delta phosphorylates tau and disrupts its binding to microtubules.. The Journal of biological chemistry, (16): [PMID:14761950]
68. Oliva, Rafael R and Pastor, Pau P.. (2004) Tau gene delN296 mutation, Parkinson's disease, and atypical supranuclear palsy.. Annals of neurology, [PMID:14991828]
69. Rossi, Giacomina G and 7 more authors.. (2004) Progressive supranuclear palsy and Parkinson's disease in a family with a new mutation in the tau gene.. Annals of neurology, [PMID:14991829]
70. Lee, Gloria G and 9 more authors.. (2004) Phosphorylation of tau by fyn: implications for Alzheimer's disease.. The Journal of neuroscience : the official journal of the Society for Neuroscience, (3): [PMID:14999081]
71. Rademakers, R R, Cruts, M M and van Broeckhoven, C C.. (2004) The role of tau (MAPT) in frontotemporal dementia and related tauopathies.. Human mutation, [PMID:15365985]
72. Liu, Fei F, Iqbal, Khalid K, Grundke-Iqbal, Inge I, Rossie, Sandra S and Gong, Cheng-Xin CX.. (2005) Dephosphorylation of tau by protein phosphatase 5: impairment in Alzheimer's disease.. The Journal of biological chemistry, (21): [PMID:15546861]
73. Zarranz, J J JJ and 16 more authors.. (2005) A novel mutation (K317M) in the MAPT gene causes FTDP and motor neuron disease.. Neurology, (10): [PMID:15883319]
74. Babu, Jeganathan Ramesh JR, Geetha, Thangiah T and Wooten, Marie W MW.. (2005) Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation.. Journal of neurochemistry, [PMID:15953362]
75. Ros, Raquel R and 9 more authors.. (2005) A new mutation of the tau gene, G303V, in early-onset familial progressive supranuclear palsy.. Archives of neurology, [PMID:16157753]
76. Yasuda, Minoru M and 5 more authors.. (2005) Phenotypic heterogeneity within a new family with the MAPT p301s mutation.. Annals of neurology, [PMID:16240366]
77. Sato, Shinji S, Cerny, Ronald L RL, Buescher, James L JL and Ikezu, Tsuneya T.. (2006) Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation.. Journal of neurochemistry, [PMID:16923168]
78. Beausoleil, Sean A SA, Villén, Judit J, Gerber, Scott A SA, Rush, John J and Gygi, Steven P SP.. (2006) A probability-based approach for high-throughput protein phosphorylation analysis and site localization.. Nature biotechnology, [PMID:16964243]
79. Hanger, Diane P DP and 8 more authors.. (2007) Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis.. The Journal of biological chemistry, (10): [PMID:17562708]
80. McGrogan, Barbara T BT, Gilmartin, Breege B, Carney, Desmond N DN and McCann, Amanda A.. (2008) Taxanes, microtubules and chemoresistant breast cancer.. Biochimica et biophysica acta, [PMID:18068131]
81. Liu, Fei F and 7 more authors.. (2009) Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease.. Brain : a journal of neurology, [PMID:19451179]
82. Puri, Rajat R, Suzuki, Toshimitsu T, Yamakawa, Kazuhiro K and Ganesh, Subramaniam S.. (2009) Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an animal model for Lafora disease.. The Journal of biological chemistry, (21): [PMID:19542233]
83. Guerreiro, Rita J RJ, Washecka, Nicole N, Hardy, John J and Singleton, Andrew A.. (2010) A thorough assessment of benign genetic variability in GRN and MAPT.. Human mutation, [PMID:20020531]
84. Rojo, Leonel E; Alzate-Morales, Jans; Saavedra, Iván N; Davies, Peter and Maccioni, Ricardo B.. (2010) Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease.. Journal of Alzheimer's disease : JAD, [PMID:20110603]
85. Smet-Nocca, Caroline C and 9 more authors.. (2011) Identification of O-GlcNAc sites within peptides of the Tau protein and their impact on phosphorylation.. Molecular bioSystems, [PMID:21327254]
86. Yoshida, Hirotaka H and Goedert, Michel M.. (2012) Phosphorylation of microtubule-associated protein tau by AMPK-related kinases.. Journal of neurochemistry, [PMID:21985311]
87. Gu, Gucci Jijuan GJ and 8 more authors.. (2013) Role of individual MARK isoforms in phosphorylation of tau at Ser²⁶² in Alzheimer's disease.. Neuromolecular medicine, [PMID:23666762]
88. Schafer, Kelsey N KN, Cisek, Katryna K, Huseby, Carol J CJ, Chang, Edward E and Kuret, Jeff J.. (2013) Structural determinants of Tau aggregation inhibitor potency.. The Journal of biological chemistry, (8): [PMID:24072703]
89. Guerreiro, Patrícia Silva PS and 5 more authors.. (2016) LRRK2 Promotes Tau Accumulation, Aggregation and Release.. Molecular neurobiology, [PMID:26014385]
90. Behnam, Mahdiyeh M and 9 more authors.. (2015) Homozygous MAPT R406W mutation causing FTDP phenotype: A unique instance of a unique mutation.. Gene, (1): [PMID:26086902]
91. Wooten, Dustin W DW and 10 more authors.. (2017) Pharmacokinetic Evaluation of the Tau PET Radiotracer 18F-T807 (18F-AV-1451) in Human Subjects.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, [PMID:27660144]
92. Vermeiren, Céline C and 8 more authors.. (2018) The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases.. Movement disorders : official journal of the Movement Disorder Society, [PMID:29278274]
93. Wang, Yi Ting YT and Edison, Paul P.. (2019) Tau Imaging in Neurodegenerative Diseases Using Positron Emission Tomography.. Current neurology and neuroscience reports, (6): [PMID:31172290]
94. Rauch, Jennifer N and 12 more authors.. (2020) LRP1 is a master regulator of tau uptake and spread.. Nature, [PMID:32296178]
95. Sandberg, Alexander and 16 more authors.. (2020) Fibrillation and molecular characteristics are coherent with clinical and pathological features of 4-repeat tauopathy caused by MAPT variant G273R.. Neurobiology of disease, [PMID:32961270]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

Zagotenemab (anti-Tau), 微管相关蛋白 tau 抑制剂

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

图片

关联靶点（人）

作用机制

安全和危险性（GHS）

技术规格说明书

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关产品

可替换产品

参考文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器